by NMS | Nov 4, 2022 | 2022, News
A week from the presentation of Nerviano Medical Sciences S.r.l. (a member of NMS Group) on NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, we’re thrilled to share the official press release from ENA 2022 of...
by NMS | Oct 31, 2022 | 2022, News
NERVIANO, 31 October 2022 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Salvatore Marengoni Galdy, M.D., has joined the...
by NMS | Oct 28, 2022 | 2022, Events, News
Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics NERVIANO, 28 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a...
by NMS | Oct 26, 2022 | 2022, Events, News
NERVIANO, 25 October 2022 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will...
by NMS Group | Oct 19, 2022 | 2022, News
Nerviano, 19, October 2022_NMS Group S.p.A., the largest oncological R&D company in Italy, announced the appointment of Mr. Lincoln Pan to its Board of Directors, effective immediately. “We are pleased to welcome my PAG colleague Lincoln to the NMS Group...
by NMS Group | Oct 17, 2022 | 2022, Events, News
Nerviano Medical Sciences S.r.l. Announces Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group...
Welcome and Check out our new motion picture!
Recent Comments